Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek J. Maetzold sold 2,368 shares of the business's stock in a transaction dated Wednesday, April 3rd. The shares were sold at an average price of $21.70, for a total value of $51,385.60. Following the completion of the sale, the insider now directly owns 67,365 shares of the company's stock, valued at $1,461,820.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Castle Biosciences Stock Performance
Shares of CSTL stock opened at $20.82 on Friday. Castle Biosciences, Inc. has a 52-week low of $9.26 and a 52-week high of $26.70. The stock's 50-day moving average price is $22.29 and its 200 day moving average price is $19.62.
Castle Biosciences (NASDAQ:CSTL - Get Free Report) last issued its quarterly earnings results on Wednesday, February 28th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.84) by $0.74. The firm had revenue of $66.12 million for the quarter, compared to analysts' expectations of $51.32 million. Castle Biosciences had a negative return on equity of 14.92% and a negative net margin of 26.15%. As a group, equities research analysts anticipate that Castle Biosciences, Inc. will post -2.41 EPS for the current year.
Hedge Funds Weigh In On Castle Biosciences
Elon’s New A.I. Device is About to Shock the World
From InvestorPlace | Ad
Using this device you see above…
Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in…
“The next step in human evolution.”
Click here to see the details because there’s a lot of money at stake.
A number of large investors have recently modified their holdings of the business. Price T Rowe Associates Inc. MD raised its stake in shares of Castle Biosciences by 2.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 16,903 shares of the company's stock worth $365,000 after buying an additional 428 shares in the last quarter. American International Group Inc. raised its stake in shares of Castle Biosciences by 5.2% during the 2nd quarter. American International Group Inc. now owns 11,130 shares of the company's stock worth $244,000 after buying an additional 552 shares in the last quarter. First Republic Investment Management Inc. raised its stake in shares of Castle Biosciences by 6.2% during the 1st quarter. First Republic Investment Management Inc. now owns 10,770 shares of the company's stock worth $245,000 after buying an additional 631 shares in the last quarter. Baird Financial Group Inc. raised its stake in shares of Castle Biosciences by 4.9% during the 1st quarter. Baird Financial Group Inc. now owns 14,349 shares of the company's stock worth $644,000 after buying an additional 674 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in Castle Biosciences by 61.2% in the 3rd quarter. Tower Research Capital LLC TRC now owns 1,821 shares of the company's stock valued at $47,000 after purchasing an additional 691 shares in the last quarter. 92.60% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Several analysts have recently weighed in on CSTL shares. Scotiabank boosted their target price on Castle Biosciences from $33.00 to $37.00 and gave the company a "sector outperform" rating in a report on Friday, March 1st. Guggenheim started coverage on Castle Biosciences in a research report on Thursday, December 14th. They issued a "buy" rating and a $25.00 price target on the stock. Finally, KeyCorp boosted their price target on Castle Biosciences from $25.00 to $28.00 and gave the company an "overweight" rating in a research report on Friday, March 1st.
Check Out Our Latest Stock Report on Castle Biosciences
Castle Biosciences Company Profile
(
Get Free Report)
Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
